Literature DB >> 22735937

Phylogenetic and biological analysis of a laboratory-generated gammaretrovirus xenotropic murine leukemia virus-related virus (XMRV).

Xiaochu Ma1, Shiying Zhou, Meili Wei, Yanxia Chen, Jiaqiang Li, Weiliang Xiong, Shibo Jiang, Chungen Pan.   

Abstract

A xenotropic murine leukemia virus-related virus (XMRV) has been reported to be an emerging pathogen associated with prostate cancer (PC) and chronic fatigue syndrome (CFS). However, recent studies have demonstrated that XMRV is a laboratory-derived virus resulting from genetic recombination between two mouse viral genomes during serial xenograft tissue transplantation. This study describes a phylogenetic analysis that compared XMRV with the ecotropic murine leukemia viruses (E-MLV), xenotropic MLV (X-MLV), and other retroviruses, including HTLV-1 and HIV-1. We found that sequences corresponding to three XMRV structural proteins (Env, Gag, and Pol) exhibited high degrees of homology with X-MLV (>91 %) and E-MLV (67-96 %), but not HTLV-1 (13-16 %) or HIV-1 (10-15 %), indicating that XMRV was derived from X-MLV and/or E-MLV. We then compared the infectivity of XMRV and E-MLV for human and murine lymphocytes, respectively. Results showed that human PBMCs were not susceptible to XMRV infection, suggesting that XMRV exhibits host cell tropism similar to E-MLV that only infects murine PBMCs. These data suggest that it is unlikely that this laboratory-generated retrovirus could cause disease in humans.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22735937     DOI: 10.1007/s11262-012-0778-x

Source DB:  PubMed          Journal:  Virus Genes        ISSN: 0920-8569            Impact factor:   2.332


  32 in total

Review 1.  No false start for novel pseudotyped vectors.

Authors:  David Avram Sanders
Journal:  Curr Opin Biotechnol       Date:  2002-10       Impact factor: 9.740

2.  Activation of a cell entry pathway common to type C mammalian retroviruses by soluble envelope fragments.

Authors:  D Lavillette; A Ruggieri; S J Russell; F L Cosset
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

3.  A domain of murine retrovirus surface protein gp70 mediates cell fusion, as shown in a novel SC-1 cell fusion system.

Authors:  K B Andersen
Journal:  J Virol       Date:  1994-05       Impact factor: 5.103

4.  Structure of a murine leukemia virus receptor-binding glycoprotein at 2.0 angstrom resolution.

Authors:  D Fass; R A Davey; C A Hamson; P S Kim; J M Cunningham; J M Berger
Journal:  Science       Date:  1997-09-12       Impact factor: 47.728

5.  Time and place of human origins from mt DNA data.

Authors:  N Saitou; K Omoto
Journal:  Nature       Date:  1987 May 28-Jun 3       Impact factor: 49.962

6.  Recombinant origin of the retrovirus XMRV.

Authors:  Tobias Paprotka; Krista A Delviks-Frankenberry; Oya Cingöz; Anthony Martinez; Hsing-Jien Kung; Clifford G Tepper; Wei-Shau Hu; Matthew J Fivash; John M Coffin; Vinay K Pathak
Journal:  Science       Date:  2011-05-31       Impact factor: 47.728

7.  Functional characterization of the N termini of murine leukemia virus envelope proteins.

Authors:  C W Lu; M J Roth
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

8.  Novel retroviral packaging cell lines: complementary tropisms and improved vector production for efficient gene transfer.

Authors:  S P Forestell; J S Dando; J Chen; P de Vries; E Böhnlein; R J Rigg
Journal:  Gene Ther       Date:  1997-06       Impact factor: 5.250

9.  Functional domains in the retroviral transmembrane protein.

Authors:  Y Zhao; L Zhu; C A Benedict; D Chen; W F Anderson; P M Cannon
Journal:  J Virol       Date:  1998-07       Impact factor: 5.103

10.  No association of xenotropic murine leukemia virus-related virus with prostate cancer or chronic fatigue syndrome in Japan.

Authors:  Rika A Furuta; Takayuki Miyazawa; Takeki Sugiyama; Hirohiko Kuratsune; Yasuhiro Ikeda; Eiji Sato; Naoko Misawa; Yasuhito Nakatomi; Ryuta Sakuma; Kazuta Yasui; Kouzi Yamaguti; Fumiya Hirayama
Journal:  Retrovirology       Date:  2011-03-17       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.